CN105362949A - Traditional Chinese medicine composition for treating rheumatoid arthritis - Google Patents
Traditional Chinese medicine composition for treating rheumatoid arthritis Download PDFInfo
- Publication number
- CN105362949A CN105362949A CN201510913408.2A CN201510913408A CN105362949A CN 105362949 A CN105362949 A CN 105362949A CN 201510913408 A CN201510913408 A CN 201510913408A CN 105362949 A CN105362949 A CN 105362949A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- rheumatoid arthritis
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating rheumatoid arthritis and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared by folium ginkgo, radix curcuma, morinda officinalis, rhizoma gastrodiae, rhizoma curcumae, pangolin scale, radix angelicae pubescentis, cortex phellodendri, semen plantaginis, fructus jujubae and radix glycyrrhizae. The traditional Chinese medicine composition for treating the rheumatoid arthritis has the advantages that the traditional Chinese medicine composition is evident in inhibiting effect on inflammation of modeling rats, foot thickness of the modeling rats can be reduced evidently, the traditional Chinese medicine composition is evident and controllable in curative effect on the rheumatoid arthritis and convenient to use, and a new clinical medicine choice is provided.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of Chinese medicine composition for the treatment of rheumatoid arthritis.
Background technology
Class rheumatoid arthritis (rheumatoidarthritis, RA) be a kind of autoimmune disorders disease, the chronic inflammatory reactive disorder of getting involved based on arthropathy and with multisystem: main manifestations is synovial hyperplasia, destruction of joint, afunction etc.RA average prevalence about 1% worldwide, the sickness rate of China is 0.32%-0.36%, is the disease that a kind of disability rate is higher, has a strong impact on the quality of life of patient.Because the RA cause of disease is not yet clear, be difficult to cure, toxic and side effects and lose clinical efficacy gradually, the state of an illness of result most of patients can not obtain permanently effective control.
Present stage has been deep into cellular level, molecular level to the research of RA, and even gene level, but due to the RA cause of disease extremely complicated, up to the present medical circle does not still capture this global problem of RA.Along with going deep into of clinical application research, the life-time service of increasing reported literature biological preparation is had likely to cause serious infection or activate recessive tuberculosis.And its treatment costs dearly, and about needs 10,000 dollars every year, even if the U.S. also only has the RA patient of 10% to accept biological preparation treatment.Chinese medicine primary disease has unique advantage, and in recent years along with the pathogenetic progress of RA, Chinese medicine study had made great progress from simple curative effect and antiinflammatory, analgesia research aspect.
Chinese patent application CN201310332120.7 discloses a kind of external medicine composition for the treatment of rheumatoid arthritis, this Chinese medicine composition is obtained by following raw material: Radix Gentianae Macrophyllae, Caulis Sinomenii, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Tripterygii Wilfordii, this Chinese medicine composition has good analgesia and antiinflammatory action, but not remarkable to the therapeutic effect of rheumatoid arthritis.
Summary of the invention
The present invention overcomes the deficiencies in the prior art, provide a kind of Chinese medicine composition for the treatment of rheumatoid arthritis, this Chinese medicine composition has bone and muscle strengthening, wind-damp dispelling, blood circulation promoting and blood stasis dispelling, eliminating stasis to stop pain, effect of invigorating the spleen to benefit the lung, be used for the treatment of Rheumatoid Arthritis remarkable, present invention also offers the preparation method of this Chinese medicine composition simultaneously.
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight: Folium Ginkgo 10-25 part, Rhizoma Curcumae Longae 9-15 part, Radix Morindae Officinalis 6-12 part, Rhizoma Gastrodiae 6-12 part, Rhizoma Curcumae 6-12 part, Squama Manis 3-10 part, Radix Angelicae Pubescentis 3-10 part, Cortex Phellodendri 3-10 part, Semen Plantaginis 3-10 part, Fructus Jujubae 3-8 part and Radix Glycyrrhizae 1-12 part.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Folium Ginkgo 10 parts, 9 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 6 parts, 6 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 6 parts, Squama Manis 3 parts, Radix Angelicae Pubescentis 3 parts, Cortex Phellodendri 3 parts, Semen Plantaginis 3 parts, 3 parts, Fructus Jujubae and 1 part, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Folium Ginkgo 18 parts, 12 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 10 parts, 10 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 10 parts, Squama Manis 6 parts, Radix Angelicae Pubescentis 6 parts, Cortex Phellodendri 6 parts, Semen Plantaginis 6 parts, 5 parts, Fructus Jujubae and 6 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Folium Ginkgo 25 parts, 15 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 12 parts, 12 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 12 parts, Squama Manis 10 parts, Radix Angelicae Pubescentis 10 parts, Cortex Phellodendri 10 parts, Semen Plantaginis 10 parts, 8 parts, Fructus Jujubae and 12 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made into capsule, tablet, powder, granule or pill.
Preferably, described Chinese medicine composition is obtained by following steps:
(1): take Folium Ginkgo, Rhizoma Curcumae Longae, Radix Morindae Officinalis, Rhizoma Gastrodiae, Rhizoma Curcumae, Squama Manis, Radix Angelicae Pubescentis, Cortex Phellodendri, Semen Plantaginis, Fructus Jujubae and Radix Glycyrrhizae respectively, decontamination, clean, dry, after mixing, be ground into coarse powder;
(2): adding described coarse powder total amount 8-15 times amount volume fraction toward above-mentioned coarse powder is the ethanol of 75-85%, microwave extraction 15-35 minute, microwave power is 400-500W, Extracting temperature is 40-50 DEG C, filter and retain filtering residue, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.20-1.30, obtains described Chinese medicine composition.
Source, the nature and flavor of the present invention's component used, return through and effect:
Folium Ginkgo: this product is the dried leaves of Ginkgoaceae plant Ginkgo biloba; Property is put down; Sweet in the mouth, hardship, puckery; GUIXIN, lung meridian; Blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, astringes the lung and relievings asthma, and changes turbid blood fat reducing.
Rhizoma Curcumae Longae: this product is the dry rhizome of zingiberaceous plant Rhizoma Curcumae Longae; Acrid in the mouth, hardship, warm in nature; Return spleen, Liver Channel; Removing blood stasis circulation of qi promoting, inducing menstruation to relieve menalgia.
Radix Morindae Officinalis: this product is the dry root of Maguireothamnus speciosus Radix Morindae Officinalis; Sweet in the mouth, pungent, tepor; Return kidney, Liver Channel; Kidney-replenishing, bone and muscle strengthening, wind-damp dispelling.
Rhizoma Gastrodiae: this product is the dry tuber of orchid Rhizoma Gastrodiae; Nature and flavor are sweet, flat; Return Liver Channel; Suppressing the hyperactive liver to relieve the wind syndrome relieving convulsion.
Rhizoma Curcumae: this product is the dry rhizome of zingiberaceous plant Rhizoma Curcumae, Guangxi zedoary or RADIX CURCUMAE; Acrid in the mouth, hardship, warm in nature; Return liver, spleen channel; Circulation of qi promoting removing blood stasis, removing food stagnancy pain relieving.
Squama Manis: this product is the scute of Manidae animal Squama Manis; Salty in the mouth, cold nature; Return liver, stomach warp; To stimulate the menstrual flow stimulating milk secretion, detumescence and apocenosis, expel wind to dredge collateral.
Radix Angelicae Pubescentis: this product is the dry root of samphire Angelica pubescens; Acrid in the mouth, hardship, tepor; Return kidney, urinary bladder channel; Expelling wind and removing dampness, numbness relieving and pain relieving.
Cortex Phellodendri: this product is the dry bark of rutaceae wampee or Cortex Phellodendri; Bitter in the mouth, cold in nature; Return kidney, urinary bladder channel; Heat clearing and damp drying, pathogenic fire purging removes steams, detoxification sore treatment.
Semen Plantaginis: this product is the seed of Plantaginaceae plant Herba Plantaginis or Plantago depressa Willd; Sweet in the mouth, cold nature; Return liver, kidney, lung, small intestine meridian; Clearing away heat and promoting diuresis, eliminating dampness by diuresis is treating stranguria, improving eyesight, eliminates the phlegm.
Fructus Jujubae: this product is the dry mature fruit of Rhamnaceae jujube Fructus Jujubae; Its sweet in the mouth, warm in nature; Return spleen, stomach warp; Invigorating the spleen and replenishing QI, nourishing blood to tranquillize the mind.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L.; Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The prescription analysis of Chinese prescription of the present invention:
Monarch drug in side of the present invention is Folium Ginkgo and Rhizoma Curcumae Longae, blood circulation promoting and blood stasis dispelling, resolving stagnation for tranquilization, removing blood stasis circulation of qi promoting, inducing menstruation to relieve menalgia; Ministerial drug is Radix Morindae Officinalis, Rhizoma Gastrodiae and Rhizoma Curcumae, kidney-replenishing, bone and muscle strengthening, wind-damp dispelling, eliminating stasis to stop pain, circulation of qi promoting removing blood stasis; Adjuvant drug is Squama Manis, Radix Angelicae Pubescentis, Cortex Phellodendri and Semen Plantaginis, expel wind to dredge collateral, expelling wind and removing dampness, clearing away heat and promoting diuresis, and eliminating dampness by diuresis is treating stranguria; Medicine is made to be Fructus Jujubae and Radix Glycyrrhizae, nourishing blood to tranquillize the mind, heat-clearing and toxic substances removing, invigorating the spleen to benefit the lung, coordinating the actions of various ingredients in a prescription, the all medicines of monarch coordinate, and collaborative promotion, complements each other, finally reach bone and muscle strengthening, wind-damp dispelling, blood circulation promoting and blood stasis dispelling, eliminating stasis to stop pain, effect of invigorating the spleen to benefit the lung, is used for the treatment of Rheumatoid Arthritis remarkable.
Compared with prior art, the present invention has following technical advantage:
1, Chinese medicine composition of the present invention is compared with the medicine of other treatment rheumatoid arthritis, in eliminating stasis to stop pain, invigorating the spleen to benefit the lung and muscle reinforcing and bone strengthening, has significant effect.
2, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, and medication effect is better, efficiently solve the morbidity root of rheumatoid arthritis, and improve the quality of life of patient.
3, Chinese medicine composition of the present invention is remarkable to modeling rat inflammation inhibitory action, significantly reduce modeling rat vola thickness, and clinical trial is evident in efficacy, is adapted at applying in the medicine of preparation treatment rheumatoid arthritis.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
embodiment 1
Described Chinese medicinal composition capsules agent is prepared from by the raw material of following parts by weight: Folium Ginkgo 10 parts, 9 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 6 parts, 6 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 6 parts, Squama Manis 3 parts, Radix Angelicae Pubescentis 3 parts, Cortex Phellodendri 3 parts, Semen Plantaginis 3 parts, 3 parts, Fructus Jujubae and 1 part, Radix Glycyrrhizae.
Preparation method is as follows:
(1): take Folium Ginkgo, Rhizoma Curcumae Longae, Radix Morindae Officinalis, Rhizoma Gastrodiae, Rhizoma Curcumae, Squama Manis, Radix Angelicae Pubescentis, Cortex Phellodendri, Semen Plantaginis, Fructus Jujubae and Radix Glycyrrhizae respectively, decontamination, clean, dry, after mixing, be ground into coarse powder;
(2): adding described coarse powder total amount 12 times amount volume fraction toward above-mentioned coarse powder is the ethanol of 75%, microwave extraction 25 minutes, microwave power is 500W, and Extracting temperature is 45 DEG C, filter and retain filtering residue, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.25, and drying under reduced pressure, is ground into powder, cross 100 mesh sieves, incapsulate in shell, every capsule medicated amount is 0.4g, obtains the capsule of Chinese medicine composition of the present invention.
embodiment 2
Described Chinese medicinal composition capsules agent is prepared from by the raw material of following parts by weight: Folium Ginkgo 18 parts, 12 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 10 parts, 10 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 10 parts, Squama Manis 6 parts, Radix Angelicae Pubescentis 6 parts, Cortex Phellodendri 6 parts, Semen Plantaginis 6 parts, 5 parts, Fructus Jujubae and 6 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3
Described Chinese medicinal composition capsules agent is prepared from by the raw material of following parts by weight: Folium Ginkgo 25 parts, 15 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 12 parts, 12 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 12 parts, Squama Manis 10 parts, Radix Angelicae Pubescentis 10 parts, Cortex Phellodendri 10 parts, Semen Plantaginis 10 parts, 8 parts, Fructus Jujubae and 12 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
chinese medicine composition of the present invention is to the drug test of rheumatoid arthritis in rats
One, testing data
1, experimental animal: healthy male Wistar rat, totally 120, body weight 150-200g, SPF level, in 8 week age, is purchased from Beijing company of dimension tonneau China.Rat adapts to nursing and tests after one week.
2, trial drug: the Chinese medicinal composition capsules agent that the embodiment of the present invention 1, embodiment 2, embodiment 3 prepare, removes capsule shells, is diluted with water to pasty state.Positive control drug is FENGSHI GUTONG JIAONANG (the accurate word Z34020025 of traditional Chinese medicines, Anhui JingFang pharmacy Co., Ltd, 0.3g/ grain), processes equally.
Two, the foundation of rheumatic arthritis animal model
1, initial immunity: get 110 rats, with 2% Nembutal sodium solution intraperitoneal injection of anesthesia rat (0.3ml/ only), in every rat root of the tail portion subcutaneous injection 0.12ml collagen emulsion (containing collagen 240 μ g), other 10 rats do not do above-mentioned process as Normal group;
2, excite immunity: after initial immunity the 7th day in both sides, rat buttocks back each subcutaneous injection 0.03ml collagen emulsion (altogether containing collagen 120 μ g).
Three, medication and grouping
110 become mould rats numbering and be divided at random: low (0.4g/kg) of the Chinese medicine composition that model group, positive controls (0.8g/kg) and the embodiment of the present invention 1, embodiment 2, embodiment 3 prepare, in (0.8g/kg), high (1.6g/kg) dosage group, often group 10.Other 10 normal mouses are as Normal group, and gavage gives equal volume distilled water, and after model group modeling, gavage gives equal volume distilled water, give corresponding medicine after the modeling of drug study group by metering gavage.Each group of gavage 28 days all continuously, once a day, record related data.
Four, arthritis scoring
Rat articular inflammation degree evaluation adopts point system (0-4 divides), and rank scores and performance are in table 1.
Table 1 rat extremities joint inflammatory score and performance
Three, result of the test is as table 2.
The parameter that the 28th day respectively organizes rat treated by table 2
Note: compare with Normal group,
△ p < 0.05,
△ △ p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01; Compare with positive controls,
#p < 0.05,
##p < 0.01.
As seen from the above table, administration is after 28 days, and model group compares with Normal group, and arthritis scoring and vola thickness significance increase (P < 0.01), and modeling success is described; Experimental data shows, Chinese medicine composition of the present invention has remarkable inhibitory action (P < 0.01) to modeling rat inflammation, significantly can reduce vola thickness (P < 0.01), and effect is better than positive controls, as can be seen here, Chinese medicine composition of the present invention has significant therapeutic effect to rheumatoid arthritis.
clinical observation on the therapeutic effect
One, diagnostic criteria
Adopt rheumatism association of U.S. revised standard in 1987.Rheumatoid arthritis feelings activity standard:
(1) moderate during rest pain;
(2) morning, the stiff time was more than or equal to 1 hour (>=6 weeks);
More than (3) three arthroncuss (≤6 weeks);
(4) joints of hand or metacarpophalangeal joints or proximal interphalangeal joint swelling (≤6 weeks);
(5) erythrocyte sedimentation rate (erythrocytesedimentationrate, ESR) is greater than 28mm/h.
Meet above 4 namely diagnosable.
Two, criterion of therapeutical effect
To joint swelling index, articular pain index, morning is stiff, grip, and ESR examines, and the improvement degree of every index is calculated as follows:
Value × 100% before (before treatment the rear value of value-treatment)/treatment;
ESR calculates:
(before treatment the rear value of value-treatment)/(before treatment value-normal value) × 100%;
(male normal value is less than or equal to 15mm/hr, and female is less than or equal to 20mm/hr)
Curative effect classification:
Calculate the improvement percent of indices, addition calculates it and on average improves percent to judge curative effect.
Effective: than before treatment after treatment, improvement rate >=70%;
Effective: than before treatment after treatment, 30%≤improvement rate < 70%;
Invalid: than before treatment after treatment, improvement rate < 30%.
Three, clinical trial
1, physical data
200 selected rheumatoid arthritis clinical volunteers patients are divided into 4 groups at random, often organize 50 people, be respectively treatment A group, treatment B group, treatment C group and matched group, respectively organize the influence factor such as age, symptom, through statistical procedures, there was no significant difference, meets a point set condition.
2, Therapeutic Method
Treatment A group: take the capsule (0.4g*60 grain/bottle) that embodiment 1 prepares, every day 2 times, each 3, serve on one month;
Treatment B group: take the capsule (0.4g*60 grain/bottle) that embodiment 2 prepares, every day 2 times, each 3, serve on one month;
Treatment C group: take the capsule (0.4g*60 grain/bottle) that embodiment 3 prepares, every day 2 times, each 3, serve on one month;
Matched group: take FENGSHI GUTONG JIAONANG (the accurate word Z34020025 of traditional Chinese medicines, Anhui JingFang pharmacy Co., Ltd, 0.3g*32 grain/box), one time 3,2 times on the one, serve on one month.
3, therapeutic outcome, as shown in table 3.
Table 3 therapeutic effect
This test adopts FENGSHI GUTONG JIAONANG as a control group, FENGSHI GUTONG JIAONANG is meticulously refined by Chinese medicines such as Radix Aconiti Preparata, Radix Aconiti Kusnezoffii Preparata, Flos Carthami, Fructus Chaenomelis, Fructus Mume, Herba Ephedrae, Radix Glycyrrhizaes and is formed, there is dispelling cold by warming the meridian, the effect of removing obstruction in the collateral to relieve pain, for the disadvantage caused by cold-damp impatency meridians, disease sees lumbar vertebrae pain, extremities joint cold type of pain; Rheumatoid arthritis is shown in above-mentioned patient.By comparing with traditional Chinese medicine composition for treating effect of the present invention, find that the total effective rate of Chinese medicine composition of the present invention each treatment group treatment rheumatoid arthritis all reaches 90%, significantly be better than matched group (74%), wherein best with the therapeutic effect for the treatment of B group, total effective rate is up to 94%, therefore embodiment 2 is preferred embodiment.Therefore, Chinese medicine composition of the present invention has good effect, the advantage that cure rate is high, can as the drug use for the treatment of rheumatoid arthritis.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (5)
1. treat the Chinese medicine composition of rheumatoid arthritis for one kind, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Folium Ginkgo 10-25 part, Rhizoma Curcumae Longae 9-15 part, Radix Morindae Officinalis 6-12 part, Rhizoma Gastrodiae 6-12 part, Rhizoma Curcumae 6-12 part, Squama Manis 3-10 part, Radix Angelicae Pubescentis 3-10 part, Cortex Phellodendri 3-10 part, Semen Plantaginis 3-10 part, Fructus Jujubae 3-8 part and Radix Glycyrrhizae 1-12 part.
2. the Chinese medicine composition for the treatment of rheumatoid arthritis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Folium Ginkgo 10 parts, 9 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 6 parts, 6 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 6 parts, Squama Manis 3 parts, Radix Angelicae Pubescentis 3 parts, Cortex Phellodendri 3 parts, Semen Plantaginis 3 parts, 3 parts, Fructus Jujubae and 1 part, Radix Glycyrrhizae.
3. the Chinese medicine composition for the treatment of rheumatoid arthritis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Folium Ginkgo 18 parts, 12 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 10 parts, 10 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 10 parts, Squama Manis 6 parts, Radix Angelicae Pubescentis 6 parts, Cortex Phellodendri 6 parts, Semen Plantaginis 6 parts, 5 parts, Fructus Jujubae and 6 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition for the treatment of rheumatoid arthritis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Folium Ginkgo 25 parts, 15 parts, Rhizoma Curcumae Longae, Radix Morindae Officinalis 12 parts, 12 parts, Rhizoma Gastrodiae, Rhizoma Curcumae 12 parts, Squama Manis 10 parts, Radix Angelicae Pubescentis 10 parts, Cortex Phellodendri 10 parts, Semen Plantaginis 10 parts, 8 parts, Fructus Jujubae and 12 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition of the treatment rheumatoid arthritis as described in any one of claim 1-4, is characterized in that: described Chinese medicine composition is made into capsule, tablet, powder, granule or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510913408.2A CN105362949A (en) | 2015-12-12 | 2015-12-12 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510913408.2A CN105362949A (en) | 2015-12-12 | 2015-12-12 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105362949A true CN105362949A (en) | 2016-03-02 |
Family
ID=55365902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510913408.2A Withdrawn CN105362949A (en) | 2015-12-12 | 2015-12-12 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105362949A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1676154A (en) * | 2004-03-30 | 2005-10-05 | 付伦志 | Chinese medicine composition for treating rheumatic rheumatoid arthritis |
| US20080044496A1 (en) * | 2006-08-03 | 2008-02-21 | Jose Angel Olalde Rangel | Arthritis phyto-nutraceutical synergistic composition |
| CN101979074A (en) * | 2010-10-27 | 2011-02-23 | 苏桂华 | Traditional Chinese medicine for treating rheumatoid arthritis |
| CN102697887A (en) * | 2012-06-26 | 2012-10-03 | 南京辰逸生物科技有限公司 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
-
2015
- 2015-12-12 CN CN201510913408.2A patent/CN105362949A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1676154A (en) * | 2004-03-30 | 2005-10-05 | 付伦志 | Chinese medicine composition for treating rheumatic rheumatoid arthritis |
| US20080044496A1 (en) * | 2006-08-03 | 2008-02-21 | Jose Angel Olalde Rangel | Arthritis phyto-nutraceutical synergistic composition |
| CN101979074A (en) * | 2010-10-27 | 2011-02-23 | 苏桂华 | Traditional Chinese medicine for treating rheumatoid arthritis |
| CN102697887A (en) * | 2012-06-26 | 2012-10-03 | 南京辰逸生物科技有限公司 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
Non-Patent Citations (2)
| Title |
|---|
| 唐蔚: "益气散寒通络法治疗类风湿性关节炎30例临床观察", 《中医药导报》 * |
| 李天庆等: "《类风湿性关节炎的中西医诊断与治疗》", 31 May 1999, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN103623280B (en) | A kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease | |
| CN104337989A (en) | Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout | |
| CN101596270B (en) | Medicine for treating chronic pharyngitis and preparation method thereof | |
| CN101983666A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method thereof | |
| CN105311210A (en) | Pharmaceutical composition for treating rheumatoid bone diseases | |
| CN105477302A (en) | Insomnia treating traditional Chinese medicine composition and preparation method thereof | |
| CN105395908A (en) | Application of medicine composition in preparing medicine for treating rheumatic arthritis | |
| CN105343808A (en) | Traditional Chinese medicine composition with weight reducing effect and preparation method of traditional Chinese medicine composition | |
| CN104547489A (en) | Use of traditional Chinese medicine composition in preparation of medicine for treating comminuted fracture | |
| CN105362949A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN105343791A (en) | Application of traditional Chinese medicine composition to preparation of drug for treating rheumatoid arthritis | |
| CN104491316B (en) | A kind of Chinese medicine preparation for the treatment of deficiency of QI in middle-JIAO type hyperplasia of prostate | |
| CN108310169A (en) | Pharmaceutical composition and preparation method thereof for preventing osteoarthritis | |
| CN107281444B (en) | Analgesic pharmaceutical composition and preparation method and application thereof | |
| CN108888742A (en) | A kind of Chinese medicine composition for treating rheumatoid arthritis | |
| CN108853443A (en) | Purposes of the Chinese medicine composition in preparation treatment medicine for treating rheumatoid arthritis | |
| CN104840814A (en) | Traditional Chinese medicine combination for treating senile femoral head necrosis | |
| CN105362999A (en) | Traditional Chinese medicine preparation for preventing and treating infantile repeated cold and preparation method thereof | |
| CN105396105A (en) | A method of preparing a traditional Chinese medicine composition for preventing and treating recurrent common cold in children | |
| CN105343577A (en) | Application of medicine composition to preparing medicine for curing rheumatic arthritis | |
| CN105327024A (en) | Traditional Chinese medicine preparation for treating rheumatoid arthritis | |
| CN105250397A (en) | Spirulina traditional Chinese medicine composition | |
| CN104758539A (en) | Traditional Chinese medicine composition for treating debilitation | |
| CN105477222A (en) | Application of traditional Chinese medicinal composition in preparing medicine for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160302 |